Letters sent to healthcare professionals in February 2016

In February 2016, a letter was sent to healthcare professionals regarding medicines containing valproate.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 10 March 2016

• Therapeutic area: Neurology, Obstetrics, gynaecology and fertility, Paediatrics and neonatology and Psychiatry

Post publication note

While correct at the time of publication, the information provided in the letter below no longer reflects the regulatory position. Valproate medicines are contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met. See Drug Safety Update April 2018 for more information.

In February 2016, a letter was sent to healthcare professionals regarding:

• medicines containing valproate and the risk of abnormal pregnancy outcomes: new communication materials (see also the associated Drug Safety Update article)

Published 10 March 2016